BioArctic AB (publ) BRCTF
30.33 USD 0.00 (+0.00%)
At closeNov 3, 2026, 4:00 PM EST
30.32 Day range 30.33
27.82 52-week range 38.75
- YTD
- -12.69%
- 1 year
- -5.69%
- Market cap
- 2.69B
- EPS (ttm)
- 0.13
- P/E ratio
- 233.31
- YTD return
- -12.69%
- 1-year return
- -5.69%
- Volume
- 200
- Avg volume
- 20
- Open
- 30.32
- Previous close
- 30.33
- Day's range
- 30.32 – 30.33
- 52-week range
- 27.82 – 38.75
- Earnings date
- Aug 26, 2026
2Y +16.96 (+126.85%)
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate -0.0344.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Jun 30, 2026 | -0.0344 | — | — | — |
| May 20, 2026 | Mar 31, 2026 | -0.03156 | 0.2514 | +0.28 | +896.58% |
| Feb 18, 2026 | Dec 31, 2025 | -0.05843 | -0.01082 | +0.05 | +81.48% |
| Nov 13, 2025 | Sep 30, 2025 | -0.12126 | -0.10458 | +0.02 | +13.76% |
| Jun 30, 2025 | Jun 30, 2025 | 0.162 | 0.114 | -0.05 | -29.63% |
| Mar 31, 2025 | Mar 31, 2025 | 1.03 | 1.15 | +0.12 | +11.65% |
News
BioArctic collaborator Novartis terminates agreement 
BioArctic's Nomination Committee appointed 
Number of shares and votes in BioArctic AB (publ) as of August 31, 2026 
BioArctic AB (publ) (BRCTF) Q2 2026 Earnings Call Transcript 
BioArctic and Mesenkia enter oncology research collaboration 
Invitation to presentation of BioArctic's second quarter report for April - June 2026 on August 26 at 9:30 a.m. CEST 
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology 
Number of shares and votes in BioArctic AB (publ) as of May 29, 2026 
Bulletin from the Annual General Meeting in BioArctic AB (publ)
Your note
Sign in to keep a note on BRCTF — it syncs with the Stock Master app.